Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine

NCT04445688 is registered in ClinicalTrials.gov with Apnimed as lead sponsor.

NCT NCT04445688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04445688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Lead sponsor
Apnimed
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2020
Completion date
December 1, 2020
Enrollment
62 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive sleep apnea